Anastrozole Plus Lonafarnib (SCH 66336) or Plus Placebo for the Treatment of Advanced Breast Cancer (P03480)
Primary Objective(s):

* To compare the activity (progression-free survival \[PFS\]) of anastrozole in combination with lonafarnib to that of anastrozole in combination with placebo in subjects with hormone-sensitive ADVANCED breast cancer.

Secondary Objective(s):

* To determine the effects of anastrozole in combination with lonafarnib on objective response, duration of response, overall survival, and safety in subjects with advanced breast cancer. To assess the exposure and pharmacokinetics of lonafarnib and anastrozole in the subject population.
Breast Cancer
DRUG: Lonafarnib|DRUG: Placebo|DRUG: anastrozole
Progression-free survival (PFS), When approximately 70 subjects have progressed
Objective response rate (adjusted RECIST criteria), duration of response, and overall survival, When approximately 70 subjects have progressed|To access the exposure and pk of lonafarnib and anastrazole in the subject population., When approximately 70 subjects have progressed
Primary Objective(s):

* To compare the activity (progression-free survival \[PFS\]) of anastrozole in combination with lonafarnib to that of anastrozole in combination with placebo in subjects with hormone-sensitive ADVANCED breast cancer.

Secondary Objective(s):

* To determine the effects of anastrozole in combination with lonafarnib on objective response, duration of response, overall survival, and safety in subjects with advanced breast cancer. To assess the exposure and pharmacokinetics of lonafarnib and anastrozole in the subject population.